Thanks ILT. Just waiting for Wednesday. My predictions are very similar to HDG on Q2 results. Basically improvement from 2022 Q1 but dismal miss from 2021 Q2.
I expect a pull back in share price
Looking for more information on CC for roll out in Europe
I believe that UK will become their primary focus for sales in Q3-Q4 until Germany approval obtained.
I think Germany most likely goes to arbitration and is resolved in November
I believe we get France approval in August and not sure about Spain approval
I believe before end of year we have a partnership in place (not selling it yet but at least a partnership) outside of Europe.
I’m not as confident that we will get approval in China by EOY and will be looking for updates the CC on whether timeline there has changed.
I see weekly scripts staying above 60k which was one of the things I’ve been eyeing closely since last CC (thanks RAF for your weekly report). KM’s strategy was to lock in 45% of commercial insurance plans with exclusivity with V and try and grow this to hopefully 50%. This would hopefully insure a slow cash burn allowing us to successfully launch in Europe.
I don’t see our efforts taking scripts from Lovaza have been successful however which was another campaign we were trying to increase scripts.
I’ve basically been putting any excess money into my bank account. I’ve got to see the following before buying more stock:
1. UK approval which was huge for me and successful so this box is checked
2. Q2 numbers and outlook moving forward (what was cash burn etc)
3. Further approvals in at least one more of the big 5 countries in EU similar to price in Sweden and UK
4. Clarity on market movement. I personally think we are early into a recession which will not be a dramatic recession with employment being much stronger than past recessions but a recession nonetheless but it will eventually bring the stock market below 30k (where it stops no clue) and will depress share price of most companies especially growth companies.
If 1,2,3 are excellent or beyond my expectations, I may still buy multiple smaller orders over the next year in spite of what I believe will be a mild to moderate recession in late 2022 and first half of 2023 with the same thoughts as you that $10 for AMRN isn’t out of the question over the next few years if EU and ROW are successful.
Just my crazy late night thoughts. I try and be transparent and wanted the board to know my current thoughts and strategies (as if anyone really cares:-). Have a good evening.